

Human IL-2/Fc Fusion Protein (Nonlytic)

CATALOG#: HF-22102**QUANTITY:** 10 µg**MOLECULAR STRUCTURE:****TRANSFECTANT CELL LINE:****STORAGE CONDITIONS:****PRODUCT STABILITY:****Ship Date:****ACTIVITY RANGE:****LOT#:****CONCENTRATION:** 0.1 mg/ml

A soluble 94 kd dimeric fusion protein consisting of human IL-2 fused to human IgG2 Fc.

NS.1 cells

Store stock solution at <-20⁰C. Store working solution at 4 ⁰C. Freeze/Thawing is not recommended.Product should retain for at least one year after shipping date when stored at <-20⁰C and the working solution should retain for at least one week at 4 ⁰C.

Measured using CTLL-2 indicator cells.

Specific Activity: 1-1.5 x10⁶ Units/mg*.**FORMULATION:** IL-2/Fc is supplied as a frozen liquid comprised of 0.22 µm sterile-filtered PBS (PH 7.4, 50 mM Sodium Phosphate, 100 mM Potassium Chloride, 150 mM NaCl) and containing no preservatives.**PRODUCTION:** Human IL-2/Fc fusion protein was purified from tissue culture supernatant of NS.1 transfectants. Purity was >98% by SDS-PAGE. The endotoxin level is ≤0.06 EU per µg of IL-2/Fc.**INFORMATION:** Interleukin-2 (IL-2) is a 133 amino acid glycoprotein with one intramolecular disulfide bond and variable glycosylation (1). It is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells, and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils, and induces mononuclear cells to secrete IFN γ and TNF α and β (1-4). Moreover, recent studies have shown that IL-2 is required for activation-induced apoptosis, an important homeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens (5, 6). A human IL-2/Fc fusion protein is made by genetically fusing IL-2 to IgG2 Fc. This fusion protein possesses both the biological functions of the IL-2 moiety and a prolonged circulating half-life determined by the Fc domain (7, 8).

*Unit defined using rhIL-2 as the reference in a CTLL2 cell proliferation assay.

1. Robb, R. J., R. M. Kutny, M. Panico, H. R. Morris, and V. Chowdhry. 1984. Amino acid sequence and post-translational modification of human interleukin 2. *Proc Natl Acad Sci U S A* 81:6486.
2. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T cell growth factor: parameters of production and a quantitative microassay for activity. *J Immunol* 120:2027.
3. Fletcher, M., and A. L. Goldstein. 1987. Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2. *Lymphokine Res* 6:45.
4. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. *Science* 240:1169.
5. Lenardo, K. M. 1991. Interleukin-2 programs mouse $\alpha\beta$ T lymphocytes for apoptosis. *Nature* 353:858.
6. Kneitz, B., T. Herrmann, S. Yonehara, and A. Schimpl. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. *Eur J Immunol* 25:2572.
7. Zheng, X. X., A. W. Steele, W. W. Hancock, K. Kawamoto, X. C. Li, P. W. Nickerson, Y. Li, Y. Tian, and T. B. Strom. 1999. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. *J Immunol* 163:4041.
8. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Triglona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, and M. G. Lewis. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [In Process Citation]. *Science* 290:486.

This Product is intended for Laboratory Research use only.**Chimerigen Laboratories**www.chimerigen.com

214 Lincoln Street, Suite 315

Allston, MA 02135

Tel: 617-779-8868

Fax: 617-779-0880